期刊文献+

预混胰岛素血糖控制不佳的超重2型糖尿病患者联合口服亚莫利疗效观察 被引量:1

下载PDF
导出
摘要 选择28例单用预混胰岛素治疗血糖控制不佳的超重2型糖尿病患者,即空腹血糖(FBG)>8.0mmol/L、餐后2小时血糖(2hPBG)>11.1mmol/L,糖化血红蛋白(HbA1c)≧7.0%,BMI≧24kg/m2者。观察组在原预混胰岛素治疗基础上加用亚莫利,观察血糖控制达标时的胰岛素剂量。治疗12周后,比较联合亚莫利前后FBG、2hPBG、糖化血红蛋白(HbA1c)、体重指数(BMI)、每天胰岛素剂量(U)等指标。结果亚莫利联合预混胰岛素治疗达标12周后,可显著降低血糖、HbA1c,而且减少预混胰岛素剂量。比较两组患者体重指数,差异没有统计学意义,但是,观察组患者调整胰岛素治疗后的体重增加较治疗组略明显。结论单用预混胰岛素治疗的超重2型糖尿病患者血糖控制不佳时,加用亚莫利后既能显著改善血糖控制,又能减少胰岛素的剂量;另外患者的体重也无明显增加。
作者 李红梅
出处 《实用糖尿病杂志》 2012年第6期33-34,共2页 Journal of Practical Diabetology
  • 相关文献

参考文献5

二级参考文献26

  • 1潘长玉,中国区合作调查组.中国糖尿病控制现状——指南与实践的差距 亚洲糖尿病治疗现状调查1998,2001及2003年中国区结果介绍[J].国外医学(内分泌学分册),2005,25(3):174-178. 被引量:396
  • 2毕艳,孙卫平,翁建平.初发2型糖尿病病人短期强化胰岛素治疗胰岛素抵抗改善的可能机制[J].中华医学杂志,2007,87(18):1284-1286. 被引量:38
  • 3Campbell RK. Glimepiride: role a new sulfonylurea in thetreatmet of type 2 biabetes mellitus. Ann Pharmacother, 1998,32:1044-1049.
  • 4Kramer W, Muller G, Girbig F, et al. Differential interaction ofgllmepiride and glibenclamide with the β-cell sulfonylurea receptor. Ⅱ . Photoaffinity labeling of a 65 Kda protein by [3H]glimepiride . Biochim Biophys Acta, 1994,1191:278-287.
  • 5Muller G, Satoh Y, Geisen K. Extrapancreafic effects of sulfonylureas : a comparison between glimepiride and conventional sulfonylureas. Diabetes Res clin Pract, 1995, 28 (suppl): s115-s121.
  • 6Boer H, Jansen M, Koerts J, et al. Prevention of weight gain in type 2 diabetes requiring insulin treatment. Diabetes Obes Metab, 2004,6 : 114-117.
  • 7Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med, 1993,329:977-986.
  • 8UK Prospective Diabetes Study (UKPDS) Group. Intensive blood- glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS33). Lancet, 1998,352:837-853.
  • 9Diabetes Control and Complications Trial Research Group and Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med, 2000. 342 : 381-389.
  • 10Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus. JAMA, 1999,281:2005-2012.

共引文献56

同被引文献19

  • 1Standl E,Janka HU.High serum insulin conceratrations in relation toother cardiovascular risk factors in macrovasculag disease of type 2 diabetes[J].Horm M etab Res,1985,15(Suppl):46-51.
  • 2Martin DB.Atherogenicity of insulin[J].Diabetes Res Clin Pratt,1988,4(Suppl):58,61.
  • 3Feldman JM,Lebovitz HE.Appraisal of the extrapancreatic actions of sulfonylurcas[J].Arch Intem M ed,1969,123:314-322.
  • 4Muller G,Satoh Y,Geisen K.Extrapancrcatic effects of sulphonylureas a comparison betw een glimepiride and conventional sulphonylureas[J].Diabetes Res Clin Pract,1995,28(Suppl):S115-S137.
  • 5Johnson JL,Wolf SL,Kabadi UM.Efficacy of insulin and sulfonylurea combination therapy in type 2 diabetes:A meta-analysis of the randomized placebo-controlled trims[J].Arch Intern M ed,1996,156:259-264.
  • 6Strowig SM,Pe-santa ML,Raskin P,et al.Comparison of insulin monotherapy and combination therapy w ith insulin and mefformin or insulin and troglimzone in type 2 diabetes[J].Diabetes Care,2002,25:2133-2140.
  • 7Hatao K,Kaku K,Matsuda M,et al.Sulfonylurea stimulates liverfructoso-2,6-bisphosphate formation in proportion to its hypoglycemicaction[J].Diabetes Res Clin Pract,1985,1:49-53.
  • 8Mori RC,Hirabaga SM,Hiram AE,et al.Glimepiride as insulin sensitizer:increased liver and muacle responses to insulin[J].Diabetes Obes Metab,2005,10(7):596-600.
  • 9韩春生.甘精胰岛素和诺和灵N分别与格列美脲联合治疗2型糖尿病疗效比较[J].中国实用医药,2008,3(12):80-83. 被引量:32
  • 10罗蕴之,王燕.格列美脲联合预混胰岛素治疗2型糖尿病疗效观察[J].临床荟萃,2012,27(23):2090-2091. 被引量:2

引证文献1

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部